Advanced Search

Revoke Authorisation Upon Renunciation, Commerciodel Medicinal Product For Human Use «Losartan And Hydrochlorothiazide Hicp».

Original Language Title: Revoca, su rinuncia, dell'autorizzazione all'immissione in commerciodel medicinale per uso umano «Losartan e Idroclorotiazide Ipca».

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
With no aRM-46/2015-3560 of February 18, 2015 's revoked, pursuant to art. 38, paragraph 9, of the Legislative Decree of April 24, 2006, no. 219, on renunciation of the HICP, Produtos Farmaceuticos, Unipessoal Lda the marketing authorisation for the medicinal product in the boxes indicated below.
Medicine: LOSARTAN And HYDROCHLOROTHIAZIDE Hicp.
Packaging: A.I.C. # 042805046-' 50 mg/12.5 mg film-coated tablets» 98 tablets in PVDC/PVC-AL;
A.I.C. # 042805034-' 50 mg/12.5 mg film-coated tablets» 56 tablets in PVDC/PVC-AL;
A.I.C. # 042805022-' 50 mg/12.5 mg film-coated tablets» 28 tablets in PVDC/PVC-AL;
A.I.C. # 042805010-' 50 mg/12.5 mg film-coated tablets» 14 tablets in PVDC/PVC-AL.
If the distribution channel were present stocks of medicine revoked, in the course of validity, the same will be disposed of not later than 180 days after the date of publication of this determination.